Servier and IDEAYA Biosciences enter into an exclusive license agreement for regulatory and commercial rights to darovasertib outside the US Darovasertib is a small molecule developed for patients with uveal melanoma, a rare type of eye cancer with high unmet medical need IDEAYA will receive an upfront payment of $210 million and up to$320 million in regulatory and commercial milestones, plus double-digit royalties on net sales IDEAYA and Servier will collaborate on the development of darovasertib and sha ...